Chemical Component Summary | |
---|---|
Name | SPIRONOLACTONE |
Synonyms | 17-HYDROXY-7ALPHA-MERCAPTO-3-OXO-17ALPHA-PREGN-4-ENE-21- CARBOXYLIC ACID; GAMMA-LACTONE ACETATE |
Identifiers | S-[(7R,8R,9S,10R,13S,14S,17R)-10,13-dimethyl-3,5'-dioxo-spiro[2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthrene-17,2'-oxolane]-7-yl] ethanethioate |
Formula | C24 H32 O4 S |
Molecular Weight | 416.57 |
Type | NON-POLYMER |
Isomeric SMILES | CC(=O)S[C@@H]1CC2=CC(=O)CC[C@@]2([C@@H]3[C@@H]1[C@@H]4CC[C@]5([C@]4(CC3)C)CCC(=O)O5)C |
InChI | InChI=1S/C24H32O4S/c1-14(25)29-19-13-15-12-16(26)4-8-22(15,2)17-5-9-23(3)18(21(17)19)6-10-24(23)11-7-20(27)28-24/h12,17-19,21H,4-11,13H2,1-3H3/t17-,18-,19+,21+,22-,23-,24+/m0/s1 |
InChIKey | LXMSZDCAJNLERA-ZHYRCANASA-N |
Chemical Details | |
---|---|
Formal Charge | 0 |
Atom Count | 61 |
Chiral Atom Count | 7 |
Bond Count | 65 |
Aromatic Bond Count | 0 |
Drug Info: DrugBank
DrugBank ID | DB00421 |
---|---|
Name | Spironolactone |
Groups | approved |
Description | Spironolactone is a potassium sparing diuretic like [eplerenone] that competitively inhibits mineralocorticoid receptors in the distal convoluted tubule to promote sodium and water excretion and potassium retention.[A11837]. Spironolactone was originally developed purely for this ability before other pharmacodynamic properties of the drug were discovered.[A11837,A178246] It is indicated to treat a number of conditions including heart failure, deem, hyperaldosteronism, adrenal hyperplasia, hypertension, and nephrotic syndrome.[Label] Off label uses of spironolactone involving its antiandrogenic activity include hirsutism, female pattern hair loss, and adult acne vulgaris.[A178135] Spironolactone is also frequently used in medical gender transition.[A178138] Spironolactone was developed in 1957, marketed in 1959, and approved by the FDA on January 21, 1960.[A178243,L6187] |
Synonyms |
|
Brand Names |
|
Indication | Spironolactone is indicated for the treatment of New York Heart Association Class III-IV heart failure, management of edema in cirrhotic adults not responsive to fluid and sodium restrictions, primary hyperaldosteronism short-term preoperatively, primary hyperaldosteronism long-term in patients with aldosterone producing adrenal adenomas that are not candidates for surgery or patients with bilarteral micro/macronodular adrenal hyperplasia, as an add-on therapy in hypertension, and in nephrotic syndrome when treatment of the disease as well as fluid and sodium restriction with other diuretics is inadequate.[Label] Spironolactone has antiandrogenic activity which leads to many of its off label uses. Spironolactone is used off label in the treatment of hirsutism, female pattern hair loss, and adult acne vulgaris.[A178135] Spironolactone is also frequently used for its antiandrogenic effects in transgender female patients due to its low cost and reducing male-pattern hair growth.[A178138] |
Categories |
|
ATC-Code | C03DA01 |
CAS number | 52-01-7 |
Drug Targets
Name | Target Sequence | Pharmacological Action | Actions |
---|---|---|---|
Mineralocorticoid receptor | METKGYHSLPEGLDMERRWGQVSQAVERSSLGPTERTDENNYMEIVNVSC... | unknown | antagonist |
Androgen receptor | MEVQLGLGRVYPRPPSKTYRGAFQNLFQSVREVIQNPGPRHPEAASAAPP... | unknown | antagonist |
Progesterone receptor | MTELKAKGPRAPHVAGGPPSPEVGSPLLCRPAAGPFPGSQTSDTLPEVSA... | unknown | agonist |
Glucocorticoid receptor | MDSKESLTPGREENPSSVLAQERGDVMDFYKTLRGGATVKVSASSPSLAV... | unknown | antagonist |
Cytochrome P450 11B2, mitochondrial | MALRAKAEVCVAAPWLSLQRARALGTRAARAPRTVLPFEAMPQHPGNRWL... | unknown | antagonist |
View More |
Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison
T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS.
Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID:21059682
Related Resource References
Resource Name | Reference |
---|---|
CCDC/CSD | ATPRCL01 |
PubChem | 5833 |
ChEBI | CHEBI:9241 |
ChEMBL | CHEMBL1393 |
Pharos | CHEMBL1393 |